Cost-effectiveness analysis of MVA85 vaccine: a new TB vaccine candidate
Includes bibliographical references. === Tuberculosis (TB) remains a major public health concern. The BCG vaccine is, currently, the only vaccine against TB and, although it provides some protection against disseminated forms of TB, its effectiveness in preventing primary infection and disease progr...
Main Author: | Channing, Liezl |
---|---|
Other Authors: | Sinanovic, Edina |
Format: | Dissertation |
Language: | English |
Published: |
University of Cape Town
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/11427/9448 |
Similar Items
-
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
by: Michele Tameris, et al.
Published: (2014-01-01) -
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
by: Anne Wajja, et al.
Published: (2017-05-01) -
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
by: Roger H Brookes, et al.
Published: (2008-08-01) -
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Kathryn T Whelan, et al.
Published: (2009-06-01) -
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)